�Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from an on-going Phase I/II clinical trial of ispinesib are scheduled to be presented as a bill poster presentation at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, to be held September lvii, 2008 at the Hilton Washington in Washington, DC.
In June 2008, as part of a notice session at the ASCO Annual Meeting, Cytokinetics proclaimed interim data from the Phase I portion of its on-going Phase I/II clinical trial of ispinesib, a novel kinesin mandril protein (KSP) inhibitor, administered as monotherapy as a first-line treatment in chemotherapy-na�ve patients with locally advanced or metastatic breast genus Cancer. The authors concluded that preliminary data suggest that ispinesib is well-tolerated when dosed on days 1 and 15 every 28 days at doses up to 12 mg/m2. Results from extra patients enrolled in the ongoing Phase I, dose-escalation portion of this clinical trial are scheduled to be presented the 2008 ASCO Breast Cancer Symposium.
Poster Presentation at ASCO Breast Cancer Symposium
Abstract #192: "A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein (KSP) Inhibitor, Dosed Every Two Weeks in Patients (pts) with Locally Advanced (LA) or Metastatic Breast Cancer (MBC) Previously Untreated with Chemotherapy (CT) for Metastatic Disease or Recurrence." (Poster Presentation on Friday, September 5, 2008, during the General Poster Session, 5:30 pm - 6:45 pm Eastern Time). The poster will be ground in the Exhibit Hall at posting board #A50 and presented by Henry Gomez, MD from Instituto Nacional de Enfermedades Neoplasicas (INEN) in Lima, Peru.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialisation of novel small molecule drugs that may call areas of significant unmet clinical necessarily. Cytokinetics' cardiovascular disease broadcast is focused to cardiac myosin, a motor protein essential to cardiac brawniness contraction. Cytokinetics' lead heighten from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. ar performing joint research focused on identifying and characterizing activators of cardiac myosin as backup and follow-on potential dose candidates to CK-1827452. Amgen has obtained an pick for an exclusive permit to develop and commercialize CK-1827452, content to Cytokinetics' development and commercial participation rights. Cytokinetics' cancer programme is focussed on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alignment established in 2001, Cytokinetics and GlaxoSmithKline (GSK) ar conducting research and development activities focused on the potential handling of cancer. Cytokinetics is developing deuce novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is sponsoring a Phase I/II clinical trial of ispinesib as monotherapy as a first-line treatment in chemotherapy-na�ve patients with locally advanced or metastatic breast malignant neoplastic disease. In addition, Cytokinetics is conducting a Phase I/II trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphomas. GSK has obtained an option for the reefer development and commercialization of ispinesib and SB-743921. Cytokinetics and GSK are conducting collaborative research activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is being developed under the strategical alliance by GSK; GSK began a Phase I clinical trial run with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potential drug nominee directed towards skeletal brawniness contractility which may be developed as a electric potential treatment for skeletal muscular tissue weakness associated with neuromuscular diseases or other atmospheric condition. All of these drug candidates and potential do drugs candidates experience arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a building complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at hTTP://www.cytokinetics.com.
This press button contains modern statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any purport or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, just are not limited to, statements relating to Cytokinetics' research and development programs, including planned presentations relating to clinical trial results, and the properties and potential benefits of Cytokinetics' drug candidates and potential difference drug candidates. Such statements are based on management's current expectations, but existent results may differ materially due to various risks and uncertainties, including, simply not modified to, electric potential difficulties or delays in the development, testing, regulative approval or production of Cytokinetics' dose candidates that could ho-hum or forbid clinical growth or product approval, including risks that current and past results of clinical trials or preclinical studies may non be indicatory of future clinical trials results, patient enrollment for clinical trials may be difficult or delayed, Cytokinetics' drug candidates may possess adverse side effects or inadequate remedial efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' power to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual attribute; Cytokinetics may incur out of the blue research and development and other costs or be unable to obtain additional financing necessary to lead development of its products; standards of care may change and others may introduce products or substitute therapies for the treatment of indications Cytokinetics' dose candidates and potential dose candidates may target; and risks and uncertainties relating to the timing and receipt of payments from Cytokinetics' partners, including milestones and royalties on future potential product sales under its quislingism agreements with such partners. For further information regarding these and other risks related to Cytokinetics' commercial enterprise, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Cytokinetics
More info
Friday 5 September 2008
Tuesday 26 August 2008
Dendreon Initiates Second Of Two New Phase 2 Trials Of PROVENGE For Prostate Cancer
�Dendreon Corporation
(Nasdaq: DNDN) announced that the Company has initiated its secondment of
deuce new Phase 2 trials of PROVENGE(R) (sipuleucel-T), Dendreon's
investigational combat-ready cellular immunotherapy for the treatment of advanced
prostate cancer. The multicenter trial, called ProACT (PROstate Active
Cellular Therapy), has begun enrolling 120 patients with metastatic,
androgen independent prostate cancer.
All patients will receive active treatment only will be randomized into
one of three cohorts which will receive PROVENGE manufactured with
different concentrations of the immunizing antigen. Patients will receive
ternary infusions of PROVENGE, each two weeks apart. The trial is being
conducted by Dendreon to research the force of antigen concentration on
CD54 upregulation, a measure of product potency, as well as the immune
response. Overall survival data will too be equanimous. The enrollment
criteria ar essentially the same as the criteria for the Phase 3 IMPACT
(IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B)
study, which completed enrolment in October 2007 and, upon receipt of
prescribed data, will serve as the elementary study for amending Dendreon's
Biologics License Application (BLA) for PROVENGE.
"We ar grateful for the continued support from patients, physicians
and affected role advocates and are proud of to be able to provide them with
access code to PROVENGE while we await results from the IMPACT trial run," stated
Mitchell H. Gold, president and chief executive officer of Dendreon.
ProACT is the second of two studies the Company is initiating. Dendreon
of late announced it had begun enrolling patients in a 40-subject,
single-center trial called NeoACT (NEOadjuvant Active Cellular
immunoTherapy), or P07-1, which is organism conducted at UCSF Helen Diller
Family Comprehensive Cancer Center.
About Prostate Cancer
Prostate cancer is the nearly common non-skin cancer in the United States
and the third most vulgar cancer cosmopolitan. More than one 1000000 men in
the United States take prostate malignant neoplastic disease, with an estimated 186,320 fresh cases
expected to be diagnosed in 2008, and approximately 28,660 hands expected to
die this year from the disease. Currently at that place are limited treatment
options for workforce with innovative, metastatic prostate cancer.
About Active Cellular Immunotherapy with PROVENGE
PROVENGE may represent the first production in a new course of fighting
cellular immunotherapies (ACIs) that are unambiguously designed to use alive
human cells to employ the patient's own resistant system with the goal of
eliciting a specific long-lasting response against crab. Active cellular
immunotherapy holds promise because it crataegus laevigata provide patients with a
meaningful clinical benefit, such as survival, combined with low toxicity.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to
target cancer and transform lives through the discovery, development and
commercialization of novel therapeutics. The Company applies its expertise
in antigen identification, engineering and cell processing to produce
active cellular immunotherapy product candidates designed to stimulate an
immune response. Dendreon is also development an orally-available small
molecule that targets Trp-p8 that could be applicable to multiple types of
genus Cancer as well as benign prostatic hyperplasia. The Company has its
headquarters in Seattle, Washington and is traded on the Nasdaq Global
Market under the symbol DNDN. For more than information approximately the Company and
its programs, visit http://www.dendreon.com.
Except for historical information contained herein, this news release
contains forward-looking statements that ar subject to risks and
uncertainties encompassing the efficaciousness of PROVENGE to treat men woe
from prostate gland cancer, risks and uncertainties surrounding the presentation
of data to the FDA and blessing of intersection applications by the FDA and
risks and uncertainties inherent in the process of discovering, developing
and commercializing drugs that ar safe and effective for use as human
therapeutics. Factors that may cause such differences include risks related
to our limited operating history, risks associated with complementary our
clinical trials, the risk that the safety and/or efficaciousness results of
existing clinical trials or from additional clinical trials for PROVENGE
will non support blessing for a biologics license, the risk of infection that the FDA
may interpret information differently than we do or ask more data or a more
rigorous analysis of data than expected, the risk that the FDA will non
approve a product for which a biologics license has been applied, the risk
that the results of a clinical trial for PROVENGE or former product may not
be indicative of results obtained in a later clinical trial, risks that we
may deficiency the financial resources and access to capital to fund needful
clinical trials or commercialization of PROVENGE, our dependency on the
efforts of third parties, and our dependence on intellectual property.
Further information on the factors and risks that could involve Dendreon's
business, financial condition and results of operations are contained in
Dendreon's public revelation filings with the U.S. Securities and Exchange
Commission, which are available at http://www.sec.gov.
Dendreon Corporation
http://www.dendreon.com
More info
(Nasdaq: DNDN) announced that the Company has initiated its secondment of
deuce new Phase 2 trials of PROVENGE(R) (sipuleucel-T), Dendreon's
investigational combat-ready cellular immunotherapy for the treatment of advanced
prostate cancer. The multicenter trial, called ProACT (PROstate Active
Cellular Therapy), has begun enrolling 120 patients with metastatic,
androgen independent prostate cancer.
All patients will receive active treatment only will be randomized into
one of three cohorts which will receive PROVENGE manufactured with
different concentrations of the immunizing antigen. Patients will receive
ternary infusions of PROVENGE, each two weeks apart. The trial is being
conducted by Dendreon to research the force of antigen concentration on
CD54 upregulation, a measure of product potency, as well as the immune
response. Overall survival data will too be equanimous. The enrollment
criteria ar essentially the same as the criteria for the Phase 3 IMPACT
(IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B)
study, which completed enrolment in October 2007 and, upon receipt of
prescribed data, will serve as the elementary study for amending Dendreon's
Biologics License Application (BLA) for PROVENGE.
"We ar grateful for the continued support from patients, physicians
and affected role advocates and are proud of to be able to provide them with
access code to PROVENGE while we await results from the IMPACT trial run," stated
Mitchell H. Gold, president and chief executive officer of Dendreon.
ProACT is the second of two studies the Company is initiating. Dendreon
of late announced it had begun enrolling patients in a 40-subject,
single-center trial called NeoACT (NEOadjuvant Active Cellular
immunoTherapy), or P07-1, which is organism conducted at UCSF Helen Diller
Family Comprehensive Cancer Center.
About Prostate Cancer
Prostate cancer is the nearly common non-skin cancer in the United States
and the third most vulgar cancer cosmopolitan. More than one 1000000 men in
the United States take prostate malignant neoplastic disease, with an estimated 186,320 fresh cases
expected to be diagnosed in 2008, and approximately 28,660 hands expected to
die this year from the disease. Currently at that place are limited treatment
options for workforce with innovative, metastatic prostate cancer.
About Active Cellular Immunotherapy with PROVENGE
PROVENGE may represent the first production in a new course of fighting
cellular immunotherapies (ACIs) that are unambiguously designed to use alive
human cells to employ the patient's own resistant system with the goal of
eliciting a specific long-lasting response against crab. Active cellular
immunotherapy holds promise because it crataegus laevigata provide patients with a
meaningful clinical benefit, such as survival, combined with low toxicity.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to
target cancer and transform lives through the discovery, development and
commercialization of novel therapeutics. The Company applies its expertise
in antigen identification, engineering and cell processing to produce
active cellular immunotherapy product candidates designed to stimulate an
immune response. Dendreon is also development an orally-available small
molecule that targets Trp-p8 that could be applicable to multiple types of
genus Cancer as well as benign prostatic hyperplasia. The Company has its
headquarters in Seattle, Washington and is traded on the Nasdaq Global
Market under the symbol DNDN. For more than information approximately the Company and
its programs, visit http://www.dendreon.com.
Except for historical information contained herein, this news release
contains forward-looking statements that ar subject to risks and
uncertainties encompassing the efficaciousness of PROVENGE to treat men woe
from prostate gland cancer, risks and uncertainties surrounding the presentation
of data to the FDA and blessing of intersection applications by the FDA and
risks and uncertainties inherent in the process of discovering, developing
and commercializing drugs that ar safe and effective for use as human
therapeutics. Factors that may cause such differences include risks related
to our limited operating history, risks associated with complementary our
clinical trials, the risk that the safety and/or efficaciousness results of
existing clinical trials or from additional clinical trials for PROVENGE
will non support blessing for a biologics license, the risk of infection that the FDA
may interpret information differently than we do or ask more data or a more
rigorous analysis of data than expected, the risk that the FDA will non
approve a product for which a biologics license has been applied, the risk
that the results of a clinical trial for PROVENGE or former product may not
be indicative of results obtained in a later clinical trial, risks that we
may deficiency the financial resources and access to capital to fund needful
clinical trials or commercialization of PROVENGE, our dependency on the
efforts of third parties, and our dependence on intellectual property.
Further information on the factors and risks that could involve Dendreon's
business, financial condition and results of operations are contained in
Dendreon's public revelation filings with the U.S. Securities and Exchange
Commission, which are available at http://www.sec.gov.
Dendreon Corporation
http://www.dendreon.com
More info
Saturday 16 August 2008
The adorable Taylor Swift on set with Jonas Brothers
Country music teen sensation, Taylor Swift, looked endearing on set of Disney's 3D film documenting the Jonas Brothers' 'Burnin Up' tour on Thursday, August 14 in Columbus Circle, New York City. Photo Credit: Splash News
August 14, 2008 () - Country music teen sentience, Taylor Swift, looked adorable on set of Disney's 3D celluloid documenting the Jonas Brothers' Burnin Up tour on Thursday, August 14 in Columbus Circle, New York City.
Swift wore a light pink dress covered with colorful embellished flower pattern. The dress up had a yellow satin trim detail on the surplice V-neckline and the hem and an all around smocking on the empire waistline to stress the shape.
Country music teen sensation, Taylor Swift, looked adorable on set of Disney's 3D cinema documenting the Jonas Brothers' 'Burnin Up' tour on Thursday, August 14 in Columbus Circle, New York City. Photo Credit: Splash News
She accessorized with shining silver ballet flats and multi bracelets on her left weapon in colors matching with her curry. Her curly blond tresses left open completed her angelic looks!
Swift, 19, had earlier made a cameo appearance as herself in Disney's approaching film Hannah Montana: The Movie, top lining her friend Miley Smith, which will be released in 2009.
While performing on August 8 at Cedar Rapids, Iowa, a town sacked by floods two months ago, Swift won the hearts of the residents by announcing a contribution of $100,000 on stage to the local Red Cross.
"The people in this town have been through so much loss this year, and my heart goes out to them," she told People. "They've stood by me, they gave me a sold-out demonstrate. You've got to pay it ahead in life - that's all I did in Cedar Rapids."
Swift was innate in Wyomissing, Pennsylvania and lives with her parents, Scott and Andrea, and her brother, Austin.
Her debut album, Taylor Swift, released in late 2006, had sold 3,021,703 copies in the U.S by June 21, 2008 and has been qualified triple pt by the RIAA in the United States.
Swift's next studio album, Fearless, is scheduled to be released in the United States on November 11, 2008.
More information
Thursday 7 August 2008
CD-R
Artist: CD-R
Genre(s):
Electronic
Discography:
2007 Vesna
Year: 2007
Tracks: 5
Aspekt - Audience - Ascent
Year: 2005
Tracks: 10
VTE - A Major Health And Financial Burden
Friday 27 June 2008
Boubacar Traore
Artist: Boubacar Traore
Genre(s):
Other
Ethnic
Instrumental
Discography:
Macire
Year: 2000
Tracks: 11
Kar Kar
Year: 1994
Tracks: 10
Allun
Monday 23 June 2008
Britney Spears Cleared Of Car Accident
Britney Spears will not be charged in relation to a photographer’s claim that she ran over his foot in November last year, with the district attorney saying “there was much commotion” at the time of the incident that “there is no proof” of her guilt.
Spears was attempting to reverse out of a parking spot at the Four Seasons Hotel in Los Angeles on November 14 while surrounded by the paparazzi, with videos of the incident circulating online.
The charge evaluation sheet uncovered by TMZ shows that the photographer filed a police report almost six months after the incident.
Deputy district attorney Joseph D. Shidler writes, “The video indicates that there was a lot of noise and confusion as the photographers were jockeying for position… The driver of the car (Spears) was driving at an extremely slow rate of speed and in a straight path. The only way the victim’s foot could have been where the video indictes it to be was by the victim placing it in that location.”
He adds, “We have no evidence to prove beyond a reasonable doubt that the suspect was aware that the victim’s foot had been struck by the car.”
Photo courtesy of Jive.
Spears was attempting to reverse out of a parking spot at the Four Seasons Hotel in Los Angeles on November 14 while surrounded by the paparazzi, with videos of the incident circulating online.
The charge evaluation sheet uncovered by TMZ shows that the photographer filed a police report almost six months after the incident.
Deputy district attorney Joseph D. Shidler writes, “The video indicates that there was a lot of noise and confusion as the photographers were jockeying for position… The driver of the car (Spears) was driving at an extremely slow rate of speed and in a straight path. The only way the victim’s foot could have been where the video indictes it to be was by the victim placing it in that location.”
He adds, “We have no evidence to prove beyond a reasonable doubt that the suspect was aware that the victim’s foot had been struck by the car.”
Photo courtesy of Jive.
Wednesday 18 June 2008
Debut novel 'Dear American Airlines' slams carrier with perfect timing
Book review: "Dear American Airlines" by Jonathan Miles (Houghton Mifflin)
There could never be a debut novel more perfectly timed to enter the world than Jonathan Miles' "Dear American Airlines."
The book is a novel-length complaint letter written by one angry American Airlines passenger who has been stranded in Chicago's O'Hare International Airport and may miss his daughter's wedding in Los Angeles.
Sound familiar? Just a few months ago, hundreds of thousands of actual American Airlines customers were stranded in airports across the country when the airline was forced to cancel 3,100 flights to check or redo something called "wiring bundles." The universe, or at least the Federal Aviation Administration, has apparently gift-wrapped a marketing campaign just for this book.
So we can credit Miles, the cocktails columnist at The New York Times, with excellent timing. But we can also credit him with a sharp and funny first novel that will outlast the particular troubles of the modern airline industry.
Bennie Ford's letter begins as a request - check that, a profane demand - for a refund of his $392.68 ticket. He's desperately trying to get to Los Angeles for the wedding of his estranged daughter, whom he hasn't seen in years.
From the first paragraph, we hear Bennie's distinctive voice: angry and outraged, literate and funny. If the cancelled flight weren't awful enough, he has to sit in a "maldesigned seat in this maldesigned airport," a limbo without clocks or cigarettes, where everyone seems to be playing sudoku, "the analgesic du jour of the travelling class."
It may seem like faint praise to call a novel "funny," as if laughter were a guilty pleasure in serious literature, something enjoyable but slightly disreputable. But what good is satire without humour? It shouldn't hurt Miles' reputation as a writer to point out a simple fact: This book will make you laugh. Out loud and repeatedly.
Bennie grew up in New Orleans, "where cirrhosis of the liver is listed as 'Natural Causes' on a death certificate." Holding his daughter in his arms for the first time, Bennie reflects, "She was so beautiful and small - a gorgeous pink speck of life. But I should also confess that I was drunk almost beyond recognition."
Later, in the middle of a domestic dispute, he finds himself locked out of his apartment in the rain. He screams his wife's name only once before it hits him: "You simply cannot shout the name Stella while standing under a window in New Orleans and hope for anything like an authentic or even mildly earnest moment."
Even in his despair, Bennie can't resist a good one-liner at his own expense.
Admittedly, whether you enjoy this novel may depend on your tolerance for a certain stock literary "guy": the brawling and boozy tough-guy poet, a little too sensitive for today's world, a little too broken inside to hold together a relationship. The template for Bennie Ford might be well-worn but Miles never falls into the cliched traps of drunken sentimentality or self-pity.
Bennie's letter soon becomes something more, a sincere confession about his failures and regrets, charting the collapse from his early years as an aspiring poet and young father, to his divorce and estrangement from his family.
He's a bad father and a miserable husband but he doesn't flinch from the truth of it. As readers, we admire his honesty and his righteous anger at modern life and modern airports. And in the end, Bennie is blessed with a moment of redemption, a touch of grace for a man stuck in O'Hare's interminable purgatory.
See Also
Subscribe to:
Posts (Atom)